GENERALIZED PUSTULAR PSORIASIS
Clinical trials for GENERALIZED PUSTULAR PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new GENERALIZED PUSTULAR PSORIASIS trials appear
Sign up with your email to follow new studies for GENERALIZED PUSTULAR PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare, severe psoriasis flares
Disease control OngoingThis study tests an oral medication, JNJ-77242113, in 19 adults with two rare and severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The goal is to see if the drug can control symptoms like widespread redness, pustules, and swelling.…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New drug shows promise for rare, severe psoriasis
Disease control OngoingThis study tests whether TAK-279 can improve symptoms of two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. About 18 adults will receive the drug for up to 52 weeks. The main goal is to see if their skin becomes clear or almost cle…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
New hope for rare skin disease: drug targets repeated flares
Disease control OngoingThis study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. About 42 adults with a history of GPP flares will receive the drug as an IV infusion at the start of a flare, with a po…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE4 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for rare skin disease: 5-year trial tests flare control
Disease control OngoingThis study looks at how safe and effective the drug spesolimab is over nearly 5 years for people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study. They receive regular doses and extr…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
GPP drug safety study in korea withdrawn before starting
Disease control TerminatedThis study was designed to track the safety and effectiveness of spesolimab in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. It planned to enroll patients starting spesolimab for the first time in routine care. However, the st…
Matched conditions: GENERALIZED PUSTULAR PSORIASIS
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 12, 2026 13:39 UTC